McNicoll Lewis & Vlak Starts Æterna Zentaris (AEZS) at Buy; Sales Revenue and Funded Phase III Trials Support Perifosine Development
Tweet Send to a Friend
McNicoll Lewis & Vlak initiates coverage on Æterna Zentaris (NASDAQ: AEZS) with a Buy. PT $5.50.
MLV analyst says, "Based ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
MLV analyst says, "Based ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
